bluuebunny/crossref_metadata_2025_split huggingface dataset:
Population survey to assess the knowledge of smoking habit and its consequences on women (w) in Spain.
Authors: Majem Margarita , Artal Angel , De Castro Javier , Felip Enriqueta , Garrido Lopez Pilar , Isla Dolores , Bujosa Juan Ramon , Cajal Rosana , Vinolas Nuria 
Published: March 2020

e12000 Background: Lung cancer (LC) w has reached epidemic proportions with a 600% increase in w’s death rate for LC. LC is the leading cause of cancer death in w in USA and the second in Spain. However, Spanish population is not aware of the significant increase in smoking and LC incidence in w. We performed a population survey to know the smokers’ characteristics and to assess the knowledge about smoking and its consequences especially in w. Methods: We conducted 1000 telephone interviews in Spanish population >18 years (y). Sample was distributed in proportion to the population by region with age and gender quotas: 48% were men (m), 52% w. Age distribution: 18-29y 16%; 30-44y 30%; 45-64y 32%; > 65y 22%. Results: The 17% and 25% of w were current and former smokers, respectively. The 27% and 38% of m were current and former smokers, respectively. People of 18-29y were the most current smokers (26%), and w smokers rate was higher than m. The 58% of w and 52% of m started smoking between 14-18y. Among students, 43% of w and 23% of m smoke. The 70% of smokers of 30-44y have tried to quit smoking, and having a relative with LC increased by 47% the possibility of quitting smoking as a young. Only 1/10 people had ever asked for their own LC risk, even if they had ever smoked or had a relative with LC. LC was the first disease named as smoking-related disease (58%). The 78% believed that nowadays more w smoke. The 60% believed that LC in w is increasing. Additionally, >40% belief that >75% of w LC have ever smoked. The 24% believed that tobacco hurts w more than m and the 55% that LC affects w more or equal than m. The 65% believed that breast cancer is the leading cause of cancer death in w in Spain and 13% that it is LC. 9/10 is aware about direct relation between tobacco and LC and the 50% believed that >50% of smokers will develop LC. The 97% believed that never smokers might also develop LC. Conclusions: Although the relation between tobacco and LC is overestimated, the 17% of w and 27% of m smoke. A large % of surveyed is aware that nowadays more w smoke, although only the 60% believed that LC in w is increasing. The highest rate of smoker w are those of 18-29y, especially among students, and >50% started smoking between 14-18y. Anti-tobacco campaigns are needed especially those targeting young w.
Smoking and prostate cancer risk in young men in Appalachian Kentucky.
Authors: Gowdar Indraneel , Mallikarjun Priya , Reddy Indraneel , Shankar Anjali , Dignan Mark 
Published: March 2020

e12004 Background: Kentucky has the highest smoking rates in the US, with 25.2% of the adult population considered current smokers compared to 18.4% nationwide (CRC, 2011 statistics), as well as high rates of chronic conditions including diabetes, heart disease, and lung cancer. In particular, the Appalachian area of Kentucky appears to have particularly high rates of both smoking and prostate cancer, beyond what is typical for the state as a whole. Recent data on prostate cancer from the Kentucky State Cancer Registry from 2004-2008 showed an incidence rate of 144 vs. 139.8 per 100,000 for "Appalachia" and Kentucky as a state, respectively. The purpose of this study is to investigate the relationship between smoking and risk of prostate cancer in Appalachian Kentucky. Methods: Data were collected on all prostate cancers diagnosed from 1996-2005 in a large hospital serving the Appalachian region. Data were collected without identifiers. Relevant statistics recorded included age at diagnosis, family history, and smoking status (classified as current smoker, non-smoker, or unknown smoking status). Results: A total of 286 patients with diagnosed prostate cancer were collected. The patients ranged from 45 to 94 years of age at diagnosis (Mean = 71, SD = 9.8). Of the 286, 89 (31.1%) had never smoked, and 94 (32.9%) were current or former cigarette smokers (Mean pack years = 25.4). To control for the age-related increase in cancer risk, patients were separated into two age groups: age 65 and younger (n=86, 30.1%), and older than 65 (n=200, 69.9%). The proportion of the younger group who smoked was significantly greater than that of the older group (44.2% vs. 28%, respectively; p= 0.009, Fischer's exact test). Conclusions: These data suggest that smoking in males younger than 65 is positively associated with an increased risk of prostate cancer in Appalachian Kentucky. Further study is needed to elucidate this relationship, as well as to evaluate any association between smoking severity and Gleason score.
Relationship of testicular cancer incidence and cellular phone use.
Authors: Somer Robert A. , Surapaneni Rakesh , Beach Douglas Francis 
Published: March 2020

e12008 Background: Because of the ubiquitous usage of cellphones, any health consequences, if found, would be of paramount importance. Many have questioned the relationship of cellphone radiofrequency waves and malignancies such as brain tumors. Because men usually store their phones in close proximately to the testicles, we analyzed the relationship between cell phone usage and testicular cancer. Methods: Testicular cancer data was obtained from SEER-9 United States Population Data Base of the National Cancer Institute. Cell phone subscription data was obtained from the World Health Organization publication. Initial data analysis was done from 1991 to 2008, with subsequent age specific and other analyses performed from 1999 to 2008. Trends over time were calculated as Annual Percentage Change of incidence rates (APC) by using log linear models. Results: Rates of United States mobile subscriptions increased exponentially since the late 1990’s reaching 88.87 percent of the population by 2008. There was no statistically significant change in incidence rates of all testicular tumors (APC 0.7; CI -0.2, 0.7), Seminoma (APC 0.2; CI 0.8, 1.1) and non-Seminoma (APC 1.4; CI -0.6, 3.4) from 1999 to 2008. In the age specific analysis, three groups showed an increase in incidence rates: all testicular cancer age 25-34 (APC 2; CI 0.6, 3.4), All testicular cancer age greater than 45 (APC 1.7; CI 0.1, 3.3) and Seminoma age 25-34 (APC 2.1; CI 0.6, 3.7). All these changes were only minor percentage increase when compared to mobile subscriptions. Conclusions: Based on incidence data, there is no convincing evidence of increased risk of testicular cancer from cell phone use. Given possible lag time incidence, continued monitoring is needed.
Higher prevalence of BRCA2 mutations among Chinese breast cancer patients in a community oncology clinic.
Authors: Keung Yi-Kong , Hu Adriana , Yeung Annie , Chan Amy , Hu Eddie 
Published: March 2020

e12017 Background: According to a large US population-based study, BRCA1 and 2 mutations occur in about 6 and 4% breast cancer cases age <45. Asians have the lowest prevalence of BRCA1 mutation among five US racial groups. The prevalence of BRCA1 and BRCA2 mutations was reported as 8.1% and 2.7% among pts with family history in Shanghai, compared to 4.9% and 7.5% respectively in Hong Kong. We would like to explore the BRCA mutations in a clinic located in an Asian-majority community in California. Methods: Consecutive female breast cancer pts selected for BRCA testing according to NCCN guidelines are retrospectively studied from 10/2009 to 10/2011. Sequencing of all translated exons and immediately adjacent intronic regions of the BRCA1 and BRCA2 was performed on the peripheral blood (Myriad, Utah). Results: Twenty-six pts were included in this study. Six pts have bilateral breast cancers; 2 synchronous and 4 metachronous with intervals of 11-13 years. Nine pts (34.6%) had BRCA2 germline mutations, of which 5 were considered deleterious and 4 of uncertain significance. Eleven pts (42.3%) had no BRCA mutation. BRCA results were unavailable in six pts because they were either not yet done or denied by health insurance. Conclusions: 1. High prevalence of BRCA2 mutation is seen in our pts selected according to NCCN guidelines. The presence of BRCA2 but not BRCA1 mutation in our study is intriguing. 2. Triple negative breast cancer is not more prevalent in BRCA2 mutation carriers. 3. Similar frequency of family history of breast/ovarian cancer is noted among pts with or without BRCA2 mutation, deleterious or of uncertain significance. The role of the BRCA2 mutation of uncertain significance needs to be further elucidated. 4. Due to the small sample size, further study is required to confirm our findings. [Table: see text]
Malignant solid neoplasms in a population of immunosuppressed patients.
Authors: De Souza Caio Silverio , Simon Sergio D. , Melo Mendes Ana Valeria , Torralvo Helena Fragata , Ziviani Luciene Fabres , Villasboas Tercia Reis , Neif Joao Antonio Junior , Miranda Raelson Rodrigues 
Published: March 2020

e12021 Background: Immunosuppression, whether caused by chronic use of immunosuppressive agents in solid organ transplant or by infection with human immunodeficiency virus (HIV), increases the risk of developing malignancies compared with the general population. This study aims to describe the profile of solid malignancies in immunosuppressed patients followed at the oncology clinic of the Federal University of São Paulo. Methods: Data were collected directly from the medical records of immunosuppressed patients followed in the Department of Clinical Oncology HSP / UNIFESP from January 2001 to January 2011 regarding sex, age, date of cancer diagnosis, tumor histology, primary site, time from beginning of immunosuppression, etiology of immunosuppression and survival,. Results: There were 46 patients (71.7% men). Median age was 47.1 years, 61% kidney transplant recipients and 39% HIV positive. The average time from the start of immunosuppression to the diagnosis of malignancy was 3.75 years in renal transplant recipients and 2.8 years in HIV positive patients. The most prevalent solid tumor in kidney transplant recipients was Kaposi's sarcoma (39.3%) followed by tumors of the gastrointestinal (GI) tract (21.4%) and genitourinary (GU) tract (14.2%). Kaposi's sarcoma was also the most prevalent cancer in HIV positive patients (44.4%) followed by head and neck (H&N) (22.2%) and GU tumors (11.1%). More than 50% of patients are alive and in follow-up. Conclusions: Kaposi's sarcoma, GI, GU and H&N tumors were the most prevalent solid neoplasms in immunosuppressed patients, in both organ transplanted and HIV patients.
Relating tissue selenium to anthropometric and receptor status in Nigerian patients with breast cancer.
Authors: Alatise Olusegun Isaac , Omoniyi-Esan Ganiyat Oluwatoyin , Lawal Olukayode O , Adesunkanmi Abdulrusheed Kayode , Agbakwuru Augustine 
Published: March 2020

e12022 Background: The aim of this study was to identify the relationship of tissue selenium to anthropometric data and receptors status among Nigerian women with breast cancer. Methods: Consecutive consenting patients who had histologically confirmed breast cancer and fibroadenoma at Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, were recruited for the study. One gram of disease breast tissue was taken for selenium analysis from the subjects. The specimens were analyzed using graphite furnace atomic absorption spectrometer. Subjects’ demographics, anthropometric and breast cancer receptor status were recorded on a standard proforma. Results: There were 127 female subjects in the 2 groups. There were 95 (74.8%) cases of fibroadenoma and 32 (25.2%) of breast cancer. While the median tissue level of selenium in patients with fibroadenoma was 0.0272mg/g with a range of 0.0124 to 0.0576mg/g. The median tissue level of selenium in patients with breast cancer was 0.0178mg/g with a range 0.0072 to 0.0436mg/g. This was statistically significant (r=-0.613; p=0.0001). The anthropometric data of the patients such as weight, height, body mass index (BMI), body surface area, mid upper arm circumference and waist over hip ratio were correlated with tissue level of selenium and only waist over hip ratio and mid upper arm circumference were statistically significant (p<0.0001, 0.049 respectively). When association of the breast cancer receptor status was tested against the tissue level of selenium, while the ER and PR receptors were significantly related to tissue level of selenium (F= 41.765, p= <0.0001; F= 3.904, p=0.021), the HER receptor status was not (F= 1.100, p= 0.467).There was negative correlation between the tissue selenium and waist over hip ratio as well as tissue estrogen receptors status. Conclusions: Tissue selenium in patients with breast cancer was significantly low than that of fibroadenoma group. Similarly, tissue selenium is inversely related to waist over hip ratio and estrogen receptor status in subjects with breast cancer. It therefore implies that low tissue selenium may be an underlying factor in the occurrence of breast cancer in Nigeria.
Risk of skeletal-related events (SREs) in patients with breast cancer (BC) and newly diagnosed metastases to bone.
Authors: Taneja Charu , Lamerato Lois , Glass Andrew , Richert-Boe Kathryn E. , Edelsberg John , Wolff Greg G. , Czapski Natalie , Chung Karen , Richhariya Akshara , Oster Gerry 
Published: March 2020

e12024 Background: Bone is a common site of metastatic involvement in patients (pts) with BC. Bony metastases (mets) are often associated with SREs (spinal cord compression [SCC], pathologic fracture [PF], surgery to bone [SB], radiotherapy to bone [RT]). Skeletal complications cause significant morbidity and mortality. Current estimates of SRE risk come principally from randomized clinical trials. Information from routine clinical practice is limited. Methods: Using the tumor registry and electronic data stores at a large US Midwest healthcare system that serves approximately 800,000 persons, we retrospectively identified all pts aged ≥18 yrs with primary BC and newly diagnosed bone mets between 1/1/95 and 12/31/09. Electronic medical records were reviewed by trained abstractors for evidence of SREs between date of bone mets diagnosis and death, loss to follow-up, or end of study. Cumulative incidence of SREs was estimated in the presence of competing risk of death. Results: We identified a total of 378 pts with primary BC and newly diagnosed bone mets; 87 pts had evidence of SREs at initial diagnosis of bone mets and were excluded from the analyses. Among the remaining 291 pts, mean (SD) age was 58.2 yrs (14.3 yrs), and 99% were women; 46% were Caucasian and 48% were African-American. Median duration of follow-up after diagnosis of bone mets was 16.1 months (mos). At 12 mos, cumulative incidence of SREs was 44.5% (SCC, 5.2%; PF, 21.0%; SCC and/or PF, 23.3%; SB, 7.6%; RT, 34.3%) (Table). Corresponding figures at 24 mos were 53.8% (SCC, 7.5%; PF, 29.3%; SCC and/or PF, 32.5%; SB, 9.4%; RT, 41.7%). Approximately one-half (45.0%) of study subjects received intravenous bisphosphonates prior to SRE. Conclusions: Pts with BC in routine clinical practice are at high risk of SREs following initial diagnosis of bone mets. [Table: see text]
Epidemiologic, clinical, and pathologic features of lymphomas at the Peruvian hospital: Hospital Nacional Cayetano Heredia.
Authors: Padilla Juan , Venegas Diego , Rodriguez Miro , Caceres Jaime , Cok Jaime , Tokumura Carolina , Ruiz Wilson , Ulloa Victor , Grados Sanchez Oswaldo Abelardo 
Published: March 2020

e12041 Background: During the decade 70’ to 90’ incidence of lymphomas in Lima, Peru increased from 3.4 to 7.5 per 100 000 females and from 6 to 8.3 per 100 000 males. We describe epidemiological, clinical and pathologic features of patients with lymphoma diagnosed at the Hospital Nacional Cayetano Heredia (HNCH), center of reference of Lima north. Methods: Retrospective study of 433 patients with lymphoma diagnosed from 1998 to 2008 at the HNCH. Results: The mean age was 44.8 years (range 1 to 93 years), the ratio was 1.5:1 for male and female respectively, 85.9% were Non Hodgkin Lymphoma (LNH). In Hodgkin diseases’ patients the mean age was 34 years and ratio male: female was 2:1; whereas, in NHL, the average age was 45.9 years and ratio male: female was 1.4:1. The more frequently symptoms were weight loss (40.5%) and lymphadenopathy (36.7%). The 55.08% were clinical stage I-II. The most frequent location was nodal (55.1%). More frequently extra nodal locations were: gastrointestinal (15.2%) and skin (10.8%). In NHL, the immunophenotype B were: B (57.8%), T (19.6%) and not determined ( 22.6%). The most common histological type was large diffuse cells lymphoma (35.8%). T-cell lymphoma adults occurs in 6.9% of cases, follicular in 4.7% and anaplastic in 4.7%.According to RECIST 1,1: 78.12% had remission completed and parcial. In Hodgkin’s disease’s treatment with ABVD was 90.97% of responses complete and parcial. During this period 23.45% of patients reported died Conclusions: Our patients with lymphoma retain the same general characteristics of the worldwide. ATLL had prevalence high relative to others series
Clinical profile and outcomes in glioblastoma multiforme: Institutional experience.
Authors: Adavikolanu Kesava Ramgopal , Syed Fayaz ahmed , Malik Monica , K Jagannathrao Naidu , Pamidighantam Suresh , Sunkavalli Venkataratnam 
Published: March 2020

e12501 Background: The standard of care for glioblastoma is surgical resection followed by adjuvant RT (radiotherapy) with concurrent and adjuvant temozolomide. Methods: Between January 2006 to December 2010, patients of glioblastoma who underwent surgery and RT to a dose of 60 Gy were analysed retrospectively. Age, KPS, extent of surgery, RPA class were noted and patients were divided into two groups, RT alone (Group I) or RT with concurrent temozolomide 75mg/m2/day followed by adjuvant temozolomide 150 mg/m2/dayX5days q28days for 6 cycles(Group II). Results: A total of 62 patients were analysed, 23 patients in group I and 39 in group II. Median age in group I was 48 years (range 16-60, 19 male, 4 female), 8(34.8%) patients underwent gross total resection, 12 (52.2%) had partial resection and 3(13%) had stereotactic biopsy. The median overall survival (OS) was six months. Median age in group II was 50 years (range 13-76, 26 male, 13 female), 17(43.6%) patients underwent gross total resection, 19(48.7%) had partial resection and 3 (7.7%) had stereotactic biopsy. The median OS was nine months (p=0.018). Patients were analysed according to the RPA class (III-VI). Median OS and 1 yr survival for group I for RPA class III,IV,V/ VI were 12, 6 and 4 months and 50%,15.3%,0% respectively. Median OS and 1 yr survival rates for group II for RPA class III, IV,V / VI were 20, 8 and 5.5 months and 66.6%, 35%, 30% respectively. On multivariate analysis age(p=0.005), KPS(p=0.05), extent of surgery(p=0.043) were found to affect survival. Conclusions: Concurrent radiotherapy and temozolomide followed by adjuvant temozolomide results in improved survival in glioblastoma.
Bevacizumab (BEV)-based therapy in the treatment of recurrent glioblastoma (GBM) in patients (PTS) treated at a Brazilian cancer center.
Authors: Munhoz Rodrigo Ramella , Braghiroli Maria Ignez Freitas Melro , Rego Juliana Florinda De Mendonga , Hoff Paulo Marcelo , Feher Olavo , Katz Artur 
Published: March 2020

e12513 Background: Temozolomide (TMZ) both concurrently and after radiation therapy constitutes the standard of care for newly diagnosed GBM PTS. BEV is FDA approved option for recurrent high-grade gliomas PTS based on the results phase II trials. Reports of the use of BEV in these setting have been limited to USA and European academic centers thus far. Methods: We conducted a cross sectional retrospective study of 39 consecutive PTS with histologically confirmed GBM that received BEV in the second or third line setting. The main objective of this analysis was to assess the efficacy and safety of BEV given “off protocol” in an unselected cohort of PTS treated at a Brazilian teaching hospital cancer center and to compare our results to those reported by North American and European academic centers. PTS received first-line treatment with TMZ plus radiotherapy and most received maintenance TMZ and received Bev-based therapy at the time of disease progression. Main endpoints were the evaluation of progression-free survival (PFS), overall survival (OS) and safety. Results: Between 2007 and 2011, 39 PTS with recurrent GBM that received BEV in second (92%) or third-line (8%) were identified. Seven PTS progressed during concomitant RT and TMZ, and 40 during or after TMZ maintenance. 72% were male; median age: 56 years (range 22-79). Most patients (89,7%) received BEV in combination with irinotecan, and the median number of cycles, regardless of combination, was 14. Reasons for BEV discontinuation were disease progression in 79,5% and toxicity in 4 patients. There was one treatment related death due to thrombocytopenia and bleeding. Twenty-four PTS (61,5%) achieved an objective response with BEV. Median PFS of the patients that received BEV in either second or third line was 7.5 months and median OS was 22.6 months. No bowel perforations or any unexpected toxicities occurred. Conclusions: This constitutes the first report of recurrent GBM PTS treated with Bev in the Southern Hemisphere. In this unselected “real life” cohort of PTS with recurrent GBM we have been able to reproduce and confirm the efficacy and safety of this agent used in the treatment of GBM in the second and third line setting.
Are generic multisource (generic) chemotherapy (CT) drugs as effective as proprietary single-source (proprietary) drugs: Evidence from in vitro CT-induced apoptosis (APOP) in non-small cell lung cancer (NSCLC), colorectal cancer (Colon CA) compared to recurrent/metastatic breast carcinoma (Breast CA).
Authors: Karimi Misagh , Rajurkar Swapnil Padmakar , Bosserman Linda D. , Rogers Karl , Davidson Dirk C. , Willis Carl Rogaston , Rutledge James , Hallquist Allan , Presant Cary A. 
Published: March 2020

e13003 Background: We have demonstrated that cancer cells from patients (Pts) with recurrent or metastatic Breast CA frequently show as much or better APOP with Generics compared to Proprietaries (separately submitted to ASCO, 2012). We have compared these observations to in vitro APOP in Pts with NSCLC and Colon CA. Methods: Purified tumor cells from Pt biopsies were placed into short term culture using the microculture kinetic (MiCK) assay. APOP was analyzed every five minutes over 48 hours. APOP was defined in kinetic units (KU) of apoptosis. Significant APOP was > 1.0 KU, significant differences between individual assays were defined as > 0.57 KU based on replicate analyses. Results from Breast CA, Colon CA and NSCLC were compared. Results: 41 Pts with NSCLC, 8 Pts with Colon CA and 67 Pts with Breast CA had successful cultures. Generics produced APOP greater than Proprietaries in 25/32 Pts with NSCLC (78%), 4/7 Pts with Colon CA (57%) and 36/43 Pts (84%) with Breast CA. Generics produced APOP = Proprietaries in 5 Pts with NSCLC (16%), 1 Pt with Colon CA (14%) and 6 Pts (14%) with Breast CA. Proprietaries produced APOP greater than Generics in 2 Pts with NSCLC (6%), 2 Pts with Colon CA (29%) and 1 Pt (2%) with Breast CA. There were 0 Pts with NSCLC, Colon CA or Breast CA in whom no drug produced significant APOP (KU less than 1.0). Proprietaries produced more APOP in Colon CA than in Breast CA (p<0.05). Detailed comparisons of drugs by disease will be presented. Conclusions: Generic drugs can produce APOP in vitro equal to or better than Proprietary drugs in most Pts with NSCLC, Colon CA, and Breast CA. The frequency of Generic drugs being at least as active as Proprietary drugs varies by disease, and was higher in Breast CA compared to Colon CA. However, the MiCK APOP assay can identify which individual Pts might require use of Proprietary drugs. These conclusions justify prospective clinical trials to confirm these in vitro results. Increased use of Generic drugs based on the APOP assay may help to control healthcare costs.